Business
InspireMD, Inc. Announces Pricing of $2.4 Million Public Offering of Common Stock
TEL AVIV, Israel, April 04, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the
About this update from Inspiremd Inc.
[{"type":"text","content":"TEL AVIV, Israel, April 04, 2019 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced the pricing of its previously announced underwritten public offering of 486,957 shares of its common stock at a price to the public of $5.00 per share. InspireMD expects to receive aggregate gross proceeds of approximately $2.4 million from the offering. The offering is expected to close on or about April 8, 2019, subject to customary closing conditions. InspireMD also granted the underwriter a 30-day option to purchase an additional 73,043 shares of its common stock.H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (\"SEC\") and was declared effective on February 23, 2018. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on April 3, 2019 and is available on the SEC's website located at http://www.sec.gov. A final prospectus supplement and accompanying prospectus will be filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from H.C. Wainwright & Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by calling (646) 975-6996 or by emailing [email protected] or at the SEC's website at http://www.sec.gov.This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet® technology to make its products the industry standard for treatment of carotid artery disease by providing outstanding acute results and durable stroke free long-term outcomes.Forward-Looking StatementsThis press release includes statements relating to the offering of InspireMD's shares of common stock, including ...